Investment research on quoted companies and funds

Hardman & Co

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise. Our clients are public and private businesses as well as fund managers, ranging from start-ups to £1 billion+ market capitalisations. Hardman & Co offers corporate research & consultancy, serving the needs of both public and private companies. We produce gold-standard research with a global reach for trading and investment companies, as well as providing market commentary and analysis. In addition, we carry out a number of bespoke investment-related assignments, including due diligence on bond listings, assessments of private company valuations and other corporate advisory services. We engage with the market through traditional and digital media, offering illuminating video content on corporate management strategy, results communication, interviews and in-house sector discussion.

Research from Hardman & Co, Hardman & Co

Research from Hardman & Co

Thematic (Sector/Industry)

United kingdom Financials / Thematic (Sector/Industry)

<ul>
<li>This month’s feature article is the Hardman &amp; Co Healthcare Index written by Dr Martin Hall, Head of Life Sciences at Hardman &amp; Co.</li>
<li>The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets.</li>
<li>Many of the 49 constituents of the index are high-risk, with micro-capitalisations and a long way from commercial success and profitability.</li>
</ul>


This month’s feature article is the Hardman &amp; Co Healthcare Index written by Dr Martin Hall, Head of Life Sciences at Hardman &amp; Co.
The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets.
Many of the 49 constituents of the index are high-risk, with micro-capitalisations and a long way from commercial success and profitability.


Hardman & Co Monthly: January 2026